Resources
4 Results (showing 1 - 4)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 1/22/2020 (updated 3/28/2024)
With opioid deaths on the rise and fentanyl deaths rapidly increasing, a crisis of this magnitude requires innovative responses at multiple intervention points, including post-overdose, as part of a comprehensive strategy to aid in the treatment of and recovery from opioid use disorders. This article explores law enforcement overdose reversal and post-resuscitation and treatment responses in the newly emerging field of pre-arrest diversion.
Posted 11/21/2019 (updated 3/28/2024)
The New York State Department of Health (NYSDOH) convened a Technical Working Group on Resuscitation Training in Naloxone Programs to ensure that overdose programs in New York State (NYS) and elsewhere are afforded the best possible resuscitation protocol guidance tailored to suspected opioid overdoses in diverse settings.
Posted 4/4/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration (FDA) announced that the makers of Narcan, an opioid overdose treatment, have the agency’s approval to make the drug widely available over the counter (OTC). Narcan is the brand name of the drug naloxone, a fast-acting overdose reversal. Until now, availability varied by state – typically restricted to licensed health care providers, approved opioid overdose programs, and first responders. This is an important consideration for rural counties given that research shows that these areas are nearly three times more likely than metropolitan counties to be a low-dispensing county for naloxone.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.